alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.
about
Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathwayThe integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cellsCollagen IV contributes to nitric oxide-induced angiogenesis of lung endothelial cellsLipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.Cell-compatible, integrin-targeted cryptophane-(129)Xe NMR biosensors.Design, synthesis, and evaluation of near infrared fluorescent multimeric RGD peptides for targeting tumorsIL-32 promotes angiogenesis.Integrins αvβ5 and αvβ3 promote latent TGF-β1 activation by human cardiac fibroblast contractionTargeted in vivo extracellular matrix formation promotes neovascularization in a rodent model of myocardial infarctionExtraction and assembly of tissue-derived gels for cell culture and tissue engineeringRGD-Binding Integrins in Head and Neck Cancers.Integrin alpha(v)beta(3)-Targeted Cancer Therapy.Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancerA safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)Halting angiogenesis by non-viral somatic gene therapy alleviates psoriasis and murine psoriasiform skin lesions.Angiogenesis in the degeneration of the lumbar intervertebral discMesenchymal stem cell migration is regulated by fibronectin through α5β1-integrin-mediated activation of PDGFR-β and potentiation of growth factor signalsIntegrin targeted therapeutics.Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.Anticancer and antiangiogenic activity of HPMA copolymer-aminohexylgeldanamycin-RGDfK conjugates for prostate cancer therapy.Vinculin activators target integrins from within the cell to increase melanoma sensitivity to chemotherapy.Generation and characterization of telomerase-transfected human lymphatic endothelial cells with an extended life spanCilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortiumaV integrins and TGF-β-induced EMT: a circle of regulationTargeting integrins for the control of tumour angiogenesis.Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate.Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.The effect of alpha-v integrin inhibition on the malignant characteristics of medulloblastoma.Selective Detection of RGD-Integrin Binding in Cancer Cells Using Tip Enhanced Raman Scattering MicroscopyITGAV and ITGA5 diversely regulate proliferation and adipogenic differentiation of human adipose derived stem cells.Inhibition of integrin alphavbeta3 prevents urokinase plasminogen activator-mediated impairment of cerebrovasodilation after cerebral hypoxia/ischemia.Phase II study of cilengitide in the treatment of refractory or relapsed high-grade gliomas in children: a report from the Children's Oncology Group.Therapeutic potential and limitations of new FAK inhibitors in the treatment of cancer.Neovascular age-related macular degeneration: opportunities for development of first-in-class biopharmaceuticals.Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?A novel treatment for glioblastoma: integrin inhibition.Advances in malignant glioma drug discovery.Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies.Tumor vasculature: the Achilles' heel of cancer?
P2860
Q24647759-9BE97347-FB92-4E9E-9DAF-AE9CB4E0102AQ28474747-C2FE9548-7E38-45B1-BC2B-52BCD55D3441Q28587552-3AF24F19-B105-4ADA-B560-BBB1C963CF26Q30366990-BF4E1454-7C7F-43E2-81AA-F1C88143C1F5Q30866826-16B70376-0BED-4DBD-A428-F206DC7308C3Q33237917-9E80421C-AD84-4C47-97D0-5EB5F433B204Q33555523-E0D87541-6C09-4E24-BE91-84D15F0846B0Q33648136-D0F98FCE-BBF3-4437-BD20-61B377CDB7CBQ33815968-EBD80666-49D3-4480-86DF-813DCEAB20D8Q33824550-373620B7-FFDD-476B-849A-B6142F692A80Q33832735-76F68738-05C3-427B-85BC-FD3A8494885FQ33983773-84C09F4E-03FA-4F84-ACE9-868297029D09Q34128953-FA4066A3-77D6-4FF5-8B97-B96DA5A8DA81Q34269566-0616CDAE-92D7-4C71-969A-909983530666Q34428875-3B1E59BC-1F00-4018-9860-6668D4526923Q34481208-BE83D68F-CC77-48D1-8AA6-96A5C94BD7E6Q34727916-1A5A2FA0-0F16-444A-9550-A4E86869B50EQ34912684-D6D0146F-5C70-4D7B-BC0A-0607B7A43D92Q34939141-973B1AA0-DF53-4478-9CCF-A85C3A79A591Q34984769-D0F5BC0B-81F2-403A-ACC6-68A55B9DBB96Q35099507-E1C06CD2-66E8-4114-A9E7-265B382CB7F9Q35102884-58BFD1C9-B4CC-4F97-9977-6A6DE601EA87Q35111316-BADE1D2C-7013-4097-8162-95492E1B1F02Q35218871-C5097D4A-5265-40CB-A7DF-19E100AE9AC1Q35791382-B1007EA3-F858-45B2-A202-CAED596603DAQ36322066-DA446463-11BD-4812-8641-E340BDC8673EQ36421314-7DE283FF-36C1-4F8E-8DFD-AC9D6F39C84DQ36788503-87D02159-067C-4FB2-A2D9-7817B0F0AA35Q37006613-692AC302-BDEF-45EC-B3F0-C462B0C73821Q37026473-7BF68BCA-C290-4852-8BED-836E1D20487DQ37057299-4D6CCA79-95B6-42E9-96A3-C9FF144C4316Q37138982-D1ADA098-EBD3-4F4C-9BD5-064141C1DFE6Q37187676-D7CA8454-AC82-4111-9056-3D616A5ABBCEQ37750751-152696E0-07D6-439E-9A11-21AF29AFB690Q37882685-516A120B-9F17-4BB0-9063-FD79AF8CFDA6Q37993124-32254EFF-BC02-4A00-A0E8-4EFA3AEF2EE1Q37997092-6D379B13-4323-48FC-B26A-BFA911AF29A7Q38014949-15565340-6008-4581-9886-261565393311Q38032282-7B8C821F-C5C0-4793-8BB2-E147C3030D64Q38057420-3B15B545-1A8A-4719-B872-09A8D7B1FBE9
P2860
alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.
@en
alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.
@nl
type
label
alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.
@en
alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.
@nl
prefLabel
alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.
@en
alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro.
@nl
P2093
P1433
P1476
alphav beta 3 and alphav beta 5 integrin antagonists inhibit angiogenesis in vitro
@en
P2093
Alfred Jonczyk
Jean-Christophe Tille
Riccardo E Nisato
P304
P356
10.1023/B:AGEN.0000011801.98187.F2
P577
2003-01-01T00:00:00Z
P6179
1051098221